DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min
HD                     :Not dialysed. Dose as in GFR <10 mL/min
HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
CAV/VVHD      :Not dialysed. Dose as in GFR=10–20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
Take with or after food Start initially with morning and evening dose; if well tolerated, can take dose once a day
OTHER INFORMATION
Warn patients to tell the doctor immediately if any of the following develop: sore throat, mouth ulcers, bruising, fever, malaise, rash, diarrhoea or non-specific illness
Blood tests should be carried out monthly, and treatment should be withdrawn if the platelets fall below 100 000/mm3, or if signs and symptoms suggestive of thrombocytopenia appear
Gold can produce nephrotic syndrome or less severe glomerular disease with proteinuria and haematuria, which are usually mild and transient. If persistent or clinically significant proteinuria develops, treatment with gold should be discontinued. Minor transient changes in renal function may also occur
Urine tests should be carried out monthly to test for proteinuria and haematuria